According to our (Global Info Research) latest study, the global Neurogenetic Testing market size was valued at US$ 794 million in 2025 and is forecast to a readjusted size of US$ 1683 million by 2032 with a CAGR of 11.4% during review period.
Neurogenetic testing is a molecular and genomic diagnostic approach used to analyze and interpret genes associated with neurological disorders. This testing helps identify whether an individual carries genetic mutations that may cause neurodegenerative diseases, epilepsy, intellectual disability, autism spectrum disorders, movement disorders, and certain hereditary neuropathies. The value of neurogenetic testing lies not only in early disease screening and clinical diagnosis, but also in guiding physicians to develop personalized treatment plans and assisting families with genetic risk assessment and reproductive planning.
With the continuous development of gene-targeted drugs, RNA therapy, gene therapy, and personalized treatment plans, accurately identifying a patient's genetic background has become a crucial foundation for formulating treatment strategies. For example, treatment options targeting specific gene defects have emerged for some hereditary neuromuscular diseases, and genetic testing can help doctors screen suitable patients for treatment. Meanwhile, in the field of neurodegenerative diseases, researchers are exploring genetic risk scores (PRS), genetic biomarkers, and disease progression prediction models for early disease identification and patient screening in clinical trials.
Many childhood neurological diseases, such as intellectual disability, autism spectrum disorder (ASD), developmental delay, and hereditary epilepsy, are closely related to genetic abnormalities. Because these diseases present with complex clinical manifestations, diagnosis based solely on symptoms often presents significant challenges; therefore, genetic testing has become an important tool for improving diagnostic rates. In recent years, an increasing number of medical institutions have begun to adopt genomic testing as a crucial step in assessing complex cases, particularly in newborn screening, diagnosis of rare childhood diseases, and early intervention, leading to a continuously increasing market demand.
Report Scope
This report is a detailed and comprehensive analysis for global Neurogenetic Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Neurogenetic Testing market size and forecasts, in consumption value ($ Million), 2021-2032
Global Neurogenetic Testing market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Neurogenetic Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Neurogenetic Testing market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neurogenetic Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neurogenetic Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Quest Diagnostics, Mayo Clinic, GeneDx, Illumina, Labcorp (Invitae/MNG Laboratories), MedGenome Labs, Connecticut Children's, CENTOGENE, Victorian Clinical Genetics Services, PacBio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Neurogenetic Testing market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Market segment by Type
Exome Sequencing
Whole Genome Sequencing
RNA Sequencing
General DNA Testing
Market segment by Disease Type
Neurodegenerative Disorders
Neuromuscular Disorders
Epilepsy Disorders
Neurodevelopmental Disorders
Genetic Brain Disorders
Market segment by Sample Type
Blood Sample Testing
Saliva Sample Testing
Cerebrospinal Fluid Testing
Tissue Sample Testing
Market segment by Application
Hospitals
Specialty Clinics
Research Institutes
Diagnostics Laboratories
Market segment by players, this report covers
Quest Diagnostics
Mayo Clinic
GeneDx
Illumina
Labcorp (Invitae/MNG Laboratories)
MedGenome Labs
Connecticut Children's
CENTOGENE
Victorian Clinical Genetics Services
PacBio
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Neurogenetic Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neurogenetic Testing, with revenue, gross margin, and global market share of Neurogenetic Testing from 2021 to 2026.
Chapter 3, the Neurogenetic Testing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Neurogenetic Testing market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurogenetic Testing.
Chapter 13, to describe Neurogenetic Testing research findings and conclusion.
Summary:
Get latest Market Research Reports on Neurogenetic Testing. Industry analysis & Market Report on Neurogenetic Testing is a syndicated market report, published as Global Neurogenetic Testing Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Neurogenetic Testing market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.